HUTCHMED (China) Limited American Depositary Shares (HCM)
Stock · NASDAQ · Health Care
$14.09as of 10/16/2026
Price chart
Active signals
HCM Signal Track Record
How signals performed across all stocks →What HCM's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 39 | +2.4% | 56% | September 1, 2026 |
| Bollinger Band Breakout | 29 | -0.6% | 48% | September 3, 2026 |
| 200-Day Moving Average TouchActive now | 24 | +2.5% | 63% | September 10, 2026 |
| Bollinger Band Breakdown | 17 | -3.6% | 47% | June 17, 2026 |
| Any 20-session window (baseline) | +0.3% | 50% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About HCM
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 1,790
- Website
- www.hutch-med.com/
Fundamentals
- 1-day range
- $13.52$13.95
- Market cap
- $2.06B
- P/E (trailing)
- 133.15
- P/E (forward)
- 53.78
- EPS (trailing)
- $0.02
- Dividend yield
- —
- Beta
- 0.88
- Avg. volume
- 69.3K
Forecasts
13 analyst ratings
HUTCHMED (China) Limited American Depositary Shares Competitors
Chosen by industry and closest market cap.
- HCMHUTCHMED (China) Limited American Depositary Shares$14.05▲ 0.79%Market cap $2.06BP/E 133.15$15.57$26
- STOKStoke Therapeutics Inc. Common Stock$24.17▼ 1.79%Market cap $2.06BP/E —$20.32$40.22
- AUPHAurinia Pharmaceuticals Inc Ordinary Shares$16.51▼ 1.31%Market cap $2.10BP/E 7.11$11.21$19.25
- ZBIOZenas BioPharma Inc. Common Stock$24.84▼ 2.20%Market cap $2.03BP/E —$13.5$44.6
- GHRSGH Research PLC Ordinary Shares$18.15▼ 3.51%Market cap $2.10BP/E —$12.04$31.44
- NUVBNuvation Bio Inc. Class A Common Stock$4.45▼ 6.32%Market cap $2.13BP/E —$3.36$9.75
- BHVNBiohaven Ltd. Common Shares$10.78▼ 5.69%Market cap $2.17BP/E —$7.48$18.57
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| HCM HUTCHMED (China) Limited American Depositary Shares | $2.06B | 133.15 | $14.05 | ▲ 0.79% | $15.57$26 |
| STOK Stoke Therapeutics Inc. Common Stock | $2.06B | — | $24.17 | ▼ 1.79% | $20.32$40.22 |
| AUPH Aurinia Pharmaceuticals Inc Ordinary Shares | $2.10B | 7.11 | $16.51 | ▼ 1.31% | $11.21$19.25 |
| ZBIO Zenas BioPharma Inc. Common Stock | $2.03B | — | $24.84 | ▼ 2.20% | $13.5$44.6 |
| GHRS GH Research PLC Ordinary Shares | $2.10B | — | $18.15 | ▼ 3.51% | $12.04$31.44 |
| NUVB Nuvation Bio Inc. Class A Common Stock | $2.13B | — | $4.45 | ▼ 6.32% | $3.36$9.75 |
| BHVN Biohaven Ltd. Common Shares | $2.17B | — | $10.78 | ▼ 5.69% | $7.48$18.57 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Top 3 British Healthcare Stocks To Watch In October 2026Yahoo · 10/9/2026
- NIOX Group And 2 Other British Healthcare StocksYahoo · 10/2/2026
- Reported Earlier, HUTCHMED Announces AstraZeneca Submitted US NDA For ORPATHYS Plus TAGRISSO In MET-Driven EGFR-Mutated NSCLC, Supported By Phase III SAFFRON Trialbenzinga · 9/29/2026
- Reported Earlier, HUTCHMED Announces AstraZeneca Submitted US NDA For ORPATHYS Plus TAGRISSO In MET-Driven EGFR-Mutated NSCLC, Supported By Phase III SAFFRON TrialBenzinga · 9/29/2026
- HUTCHMED Announces Submission of US NDA for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung CancerYahoo · 9/29/2026
- HUTCHMED Initiates Global Trial of KRAS-EGFR-Antibody Conjugate Therapy HMPL-A830 in Patients with Solid TumorsYahoo · 9/28/2026
- GSK Bets on HUTCHMED to Expand its Multi-Billion-Dollar Oncology OpportunityYahoo · 9/24/2026
- HUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2026Yahoo · 9/24/2026
- 5 Undervalued Oncology Stocks Wall Street Is OverlookingSeekingAlpha · 9/18/2026
Insider Activity
Insider Actions →- Chiu Lorenso · May 20, 2026 · J8.9K
- Chiu Lorenso · May 20, 2026 · J5.2K
- Cheng Chig Fung · May 20, 2026 · J26.3K
- Cheng Chig Fung · May 20, 2026 · J30.2K
- Nixon Charles George Rupert · May 20, 2026 · J7.6K
- Nixon Charles George Rupert · May 20, 2026 · J7.4K
- Su Wei-guo · May 20, 2026 · J75.1K
- Su Wei-guo · May 20, 2026 · J132.9K
Institutional Ownership
March 31, 2026
- Total shares held
- 4.27M
- Total value held
- $63.57M
- Institutional holders
- 52
- Unknown1.48M
- Unknown837.5K
- Unknown304.8K
- Unknown291.2K
- Unknown255.5K
- Unknown232.2K
- Unknown132.1K
- Unknown106.5K
- Unknown85.0K
- Unknown76.5K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
HUTCHMED US NDA for ORPATHYS-TAGRISSO Combo
HUTCHMED (China) has submitted a US New Drug Application for the ORPATHYS and TAGRISSO combination in lung cancer. This regulatory step is a key milestone for the company's pipeline in the US market. The stock is currently trading below its 52-week high, reflecting ongoing valuation pressures despite this development.
HUTCHMED US NDA for ORPATHYS-TAGRISSO Combo. HUTCHMED (China) has submitted a US New Drug Application for the ORPATHYS and TAGRISSO combination in lung cancer. This regulatory step is a key milestone for the company's pipeline in the US market. The stock is currently trading below its 52-week high, reflecting ongoing valuation pressures despite this development.